{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T08:35:04Z","timestamp":1788942904559,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-024-13153-1","type":"journal-article","created":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T07:56:40Z","timestamp":1731311800000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Head-to-head study of [18F]FAPI-04 PET\/CT and [18F]FDG PET\/CT for non-invasive assessment of liver cancer and its immunohistochemical markers"],"prefix":"10.1186","volume":"24","author":[{"given":"Zhiying","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhidong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,11]]},"reference":[{"key":"13153_CR1","doi-asserted-by":"publisher","first-page":"802","DOI":"10.20892\/j.issn.2095-3941.2021.0661","volume":"19","author":"T Yan","year":"2022","unstructured":"Yan T, Yu L, Zhang N, Peng C, Su G, Jing Y, et al. The advanced development of molecular targeted therapy for hepatocellular carcinoma. Cancer Biol Med. 2022;19:802\u201317.","journal-title":"Cancer Biol Med"},{"key":"13153_CR2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.cld.2010.10.001","volume":"14","author":"ES Chan","year":"2010","unstructured":"Chan ES, Yeh MM. The use of immunohistochemistry in liver tumors. Clin Liver Dis. 2010;14:687\u2013703.","journal-title":"Clin Liver Dis"},{"key":"13153_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.5152\/eurasianjmed.2019.19016","volume":"52","author":"A Maman","year":"2020","unstructured":"Maman A, Sahin A, Ayan AK. The relationship of SUV Value in PET-CT with Tumor differentiation and tumor markers in gastric Cancer. Eurasian J Med. 2020;52:67\u201372.","journal-title":"Eurasian J Med"},{"key":"13153_CR4","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.2214\/AJR.18.19501","volume":"211","author":"K Ozturk","year":"2018","unstructured":"Ozturk K, Gencturk M, Caicedo-Granados E, Li F, Cayci Z. Utility of FDG PET\/CT in the characterization of Sinonasal neoplasms: analysis of standardized uptake value parameters. Am J Roentgenol. 2018;211:1354\u201360.","journal-title":"Am J Roentgenol"},{"key":"13153_CR5","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/1471-2407-14-130","volume":"14","author":"BA Hoeben","year":"2014","unstructured":"Hoeben BA, Starmans MH, Leijenaar RT, Dubois LJ, van der Kogel AJ, Kaanders JH, et al. Systematic analysis of 18F-FDG PET and metabolism, proliferation and hypoxia markers for classification of head and neck tumors. BMC Cancer. 2014;14:130.","journal-title":"BMC Cancer"},{"key":"13153_CR6","doi-asserted-by":"publisher","first-page":"1031581","DOI":"10.3389\/fonc.2023.1031581","volume":"13","author":"PF Gao","year":"2023","unstructured":"Gao PF, Lu N, Liu W. MRI VS. FDG-PET for diagnosis of response to neoadjuvant therapy in patients with locally advanced rectal cancer. Front Oncol. 2023;13:1031581.","journal-title":"Front Oncol"},{"key":"13153_CR7","doi-asserted-by":"publisher","first-page":"1210982","DOI":"10.3389\/fnume.2023.1210982","volume":"3","author":"NE Nyakale","year":"2023","unstructured":"Nyakale NE, Aldous C, Gutta AA, Khuzwayo X, Harry L, Sathekge MM. Emerging theragnostic radionuclide applications for hepatocellular carcinoma. Front Nucl Med. 2023;3:1210982.","journal-title":"Front Nucl Med"},{"key":"13153_CR8","doi-asserted-by":"publisher","first-page":"160","DOI":"10.2967\/jnumed.120.244806","volume":"62","author":"A Altmann","year":"2021","unstructured":"Altmann A, Haberkorn U, Siveke J. The latest developments in imaging of fibroblast activation protein. J Nucl Med. 2021;62:160\u20137.","journal-title":"J Nucl Med"},{"key":"13153_CR9","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.2967\/jnumed.123.265486","volume":"64","author":"T Watabe","year":"2023","unstructured":"Watabe T, Naka S, Tatsumi M, Kamiya T, Kimura T, Shintani Y, et al. Initial evaluation of [18F]FAPI-74 PET for various histopathologically confirmed cancers and Benign lesions. J Nucl Med. 2023;64:1225\u201331.","journal-title":"J Nucl Med"},{"key":"13153_CR10","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00259-021-05488-9","volume":"49","author":"K Dendl","year":"2022","unstructured":"Dendl K, Finck R, Giesel FL, Kratochwil C, Lindner T, Mier W, et al. FAP imaging in rare cancer entities-first clinical experience in a broad spectrum of malignancies. Eur J Nucl Med Mol I. 2022;49:721\u201331.","journal-title":"Eur J Nucl Med Mol I"},{"key":"13153_CR11","doi-asserted-by":"publisher","first-page":"7197","DOI":"10.3390\/ijms25137197","volume":"25","author":"F Manuppella","year":"2024","unstructured":"Manuppella F, Pisano G, Taralli S, Caldarella C, Calcagni ML. Diagnostic performances of PET\/CT using fibroblast activation protein inhibitors in patients with primary and metastatic liver tumors: a Comprehensive Literature Review. Int J Mol Sci. 2024;25:7197.","journal-title":"Int J Mol Sci"},{"key":"13153_CR12","doi-asserted-by":"publisher","first-page":"490","DOI":"10.2214\/AJR.22.28402","volume":"220","author":"Z Gege","year":"2023","unstructured":"Gege Z, Xueju W, Bin J. Head-To-Head comparison of 68Ga-FAPI PET\/CT and FDG PET\/CT for the detection of peritoneal metastases: systematic review and Meta-analysis. Am J Roentgenol. 2023;220:490\u20138.","journal-title":"Am J Roentgenol"},{"key":"13153_CR13","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1007\/s11307-022-01749-7","volume":"24","author":"S Wegen","year":"2022","unstructured":"Wegen S, van Heek L, Linde P, Claus K, Akuamoa-Boateng D, Baues C, et al. Head-to-Head comparison of [68Ga]Ga-FAPI-46-PET\/CT and [18F]F-FDG-PET\/CT for Radiotherapy Planning in Head and Neck Cancer. Mol Imaging Biol. 2022;24:986\u201394.","journal-title":"Mol Imaging Biol"},{"key":"13153_CR14","doi-asserted-by":"publisher","first-page":"693640","DOI":"10.3389\/fonc.2021.693640","volume":"11","author":"H Wang","year":"2021","unstructured":"Wang H, Zhu W, Ren S, Kong Y, Huang Q, Zhao J, et al. 68Ga-FAPI-04 Versus 18F-FDG PET\/CT idetectionection of Hepatocellular Carcinoma. Front Oncol. 2021;11:693640.","journal-title":"Front Oncol"},{"key":"13153_CR15","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1007\/s00259-020-05095-0","volume":"48","author":"W Guo","year":"2021","unstructured":"Guo W, Pang Y, Yao L, Zhao L, Fan C, Ke J, et al. Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [68Ga]Ga-FAPI-04 PET\/CT versus MRI and [18F]-FDG PET\/CT. Eur J Nucl Med Mol I. 2021;48:1604\u201317.","journal-title":"Eur J Nucl Med Mol I"},{"key":"13153_CR16","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s00259-022-06022-1","volume":"50","author":"J Zhang","year":"2023","unstructured":"Zhang J, He Q, Jiang S, Li M, Xue H, Zhang D, et al. [18F]FAPI PET\/CT in the evaluation of focal liver lesions with [18F]FDG non-avidity. Eur J Nucl Med Mol I. 2023;50:937\u201350.","journal-title":"Eur J Nucl Med Mol I"},{"key":"13153_CR17","first-page":"77","volume":"33","author":"P Singh","year":"2024","unstructured":"Singh P, Singhal T, Parida GK, Rahman A, Agrawal K. Diagnostic performance of FAPI PET\/CT vs. 18F-FDG PET\/CT in evaluation of liver tumors: a systematic review and Meta-analysis. Mol Imaging Radionuc. 2024;33:77\u201389.","journal-title":"Mol Imaging Radionuc"},{"key":"13153_CR18","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1007\/s11307-022-01732-2","volume":"24","author":"D Siripongsatian","year":"2022","unstructured":"Siripongsatian D, Promteangtrong C, Kunawudhi A, Kiatkittikul P, Boonkawin N, Chinnanthachai C, et al. Comparisons of quantitative parameters of Ga-68-Labelled fibroblast activating protein inhibitor (FAPI) PET\/CT and [18F]F-FDG PET\/CT in patients with liver malignancies. Mol Imaging Biol. 2022;24:818\u201329.","journal-title":"Mol Imaging Biol"},{"key":"13153_CR19","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.2967\/jnumed.122.265215","volume":"64","author":"KM Pabst","year":"2023","unstructured":"Pabst KM, Trajkovic-Arsic M, Cheung PFY, Ballke S, Steiger K, Bartel T, et al. Superior Tumor Detection for 68Ga-FAPI-46 Versus 18F-FDG PET\/CT and conventional CT in patients with Cholangiocarcinoma. J Nucl Med. 2023;64:1049\u201355.","journal-title":"J Nucl Med"},{"key":"13153_CR20","doi-asserted-by":"crossref","first-page":"e080523216636","DOI":"10.2174\/1573405620666230508105758","volume":"20","author":"BK Sokmen","year":"2024","unstructured":"Sokmen BK, Inan N. 18F-FDG PET\/Mprimaryrhepaticemalignanciesancies: Differediagnosisgnosihistologicogradingrading. Curr Med Imaging. 2024;20:e080523216636.","journal-title":"Curr Med Imaging"},{"key":"13153_CR21","doi-asserted-by":"publisher","first-page":"901","DOI":"10.4103\/jcrt.JCRT_217_16","volume":"17","author":"M Dursun","year":"2021","unstructured":"Dursun M, Ozbek E, Otunctemur A, Besiroglu H. Differentiating renal pelvic cancer from renal cell carcinoma with 18-fluorodeoxyglucose positron emission tomography-computed tomography. J Cancer Res Ther. 2021;17:901\u20135.","journal-title":"J Cancer Res Ther"},{"key":"13153_CR22","first-page":"172","volume":"65","author":"WD Hu","year":"2021","unstructured":"Hu WD, Wang HC, Wang YB, Cui LL, Chen XH. Correlation study on 18F-FDG PET\/CT metabolic characteristics of primary lesion with clinical stage in lung cancer. Q J Nucl Med Mol Im. 2021;65:172\u20137.","journal-title":"Q J Nucl Med Mol Im"},{"key":"13153_CR23","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1097\/MNM.0000000000001668","volume":"44","author":"Y Pu","year":"2023","unstructured":"Pu Y, Wang C, Xie R, Zhao S, Li K, Yang C, et al. Role of 18F-fluorodeoxyglucose PET\/computed tomography in the diagnosis and treatment response assessment of primary bone lymphoma. Nucl Med Commun. 2023;44:318\u201329.","journal-title":"Nucl Med Commun"},{"key":"13153_CR24","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.2147\/IJGM.S293998","volume":"14","author":"Y Li","year":"2021","unstructured":"Li Y, Liu C, Wang B, Hu X, Gong C, Zhao Y, et al. Prediction of pretreatment 18F-FDG-PET\/CT parameters on the outcome of first-line therapy in patients with metastatic breast Cancer. Int J Gen Med. 2021;14:1797\u2013809.","journal-title":"Int J Gen Med"},{"key":"13153_CR25","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.anl.2024.04.008","volume":"51","author":"T Yoshikawa","year":"2024","unstructured":"Yoshikawa T, Endo K, Moriyama-Kita M, Ueno T, Nakanishi Y, Dochi H, et al. Association of 18F-fluorodeoxyglucose uptake with the expression of metabolism- related molecules in papillary thyroid cancer. Auris Nasus Larynx. 2024;51:696\u2013702.","journal-title":"Auris Nasus Larynx"},{"key":"13153_CR26","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1097\/MNM.0000000000001133","volume":"41","author":"E Arslan","year":"2020","unstructured":"Arslan E, Aksoy T, Can Trabulus FD, Kelten Talu C, Yeni B, \u00c7ermik TF. The association of 18F-fluorodeoxyglucose PET\/computed tomography parameters with tissue gastrin-releasing peptide receptor and integrin \u03b1v\u03b23 receptor levels in patients with breast cancer. Nucl Med Commun. 2020;41:260\u20138.","journal-title":"Nucl Med Commun"},{"key":"13153_CR27","doi-asserted-by":"publisher","first-page":"e27100","DOI":"10.1097\/MD.0000000000027100","volume":"100","author":"D Wang","year":"2021","unstructured":"Wang D, Li Y, Chen X, Li P. Prognostic significance of volume-based 18F-FDG PET\/CT parameters and correlation with PD-L1 expression in patients with surgically resected lung adenocarcinoma. Medicine. 2021;100:e27100.","journal-title":"Medicine"},{"key":"13153_CR28","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1007\/s00259-020-04882-z","volume":"48","author":"X Shi","year":"2021","unstructured":"Shi X, Xing H, Yang X, Li F, Yao S, Zhang H, et al. Fibroblast imaging of hepatic carcinoma with 68Ga-FAPI-04 PET\/CT: a pilot study in patients with suspected hepatic nodules. Eur J Nucl Med Mol I. 2021;48:196\u2013203.","journal-title":"Eur J Nucl Med Mol I"},{"key":"13153_CR29","doi-asserted-by":"publisher","first-page":"e15556","DOI":"10.1200\/jco.2009.27.15_suppl.e15556","volume":"27","author":"L Liu","year":"2009","unstructured":"Liu L, Huang Y, Guo J, Wang Z, Song D. Correlation between FDG PET\/CT and the expression of Ki-67, MMP-2, micro-vessel density (MVD), and pathological grading in squamous cell carcinoma of the esophagus. J Clin Oncol. 2009;27:e15556.","journal-title":"J Clin Oncol"},{"key":"13153_CR30","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1097\/RLU.0000000000004593","volume":"48","author":"R Lib\u00e9","year":"2023","unstructured":"Lib\u00e9 R, Pais A, Violon F, Guignat L, Bonnet F, Huillard O, et al. Positive correlation between 18F-FDG uptake and tumor-proliferating Antigen Ki-67 expression in Adrenocortical Carcinomas. Clin Nucl Med. 2023;48:381\u20136.","journal-title":"Clin Nucl Med"},{"key":"13153_CR31","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.2967\/jnumed.120.257915","volume":"62","author":"N Hirmas","year":"2021","unstructured":"Hirmas N, Leyh C, Sraieb M, Barbato F, Schaarschmidt BM, Umutlu L, et al. 68Ga-PSMA-11 PET\/CT Improves Tumor Detection and Impacts Managemepatientstients with Hepatocellular Carcinoma. J Nucl Med. 2021;62:1235\u201341.","journal-title":"J Nucl Med"},{"key":"13153_CR32","doi-asserted-by":"crossref","unstructured":"An S, Zhang D, Zhang Y, Wang C, Shi L, Wei W et al. GPC3-targeted immunoPET imaging of hepatocellular carcinomas. Eur J Nucl Med Mol Imaging. 2022, 49:2682\u20132692.","DOI":"10.1007\/s00259-022-05723-x"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13153-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-13153-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13153-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T20:02:05Z","timestamp":1731355325000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-13153-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,11]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["13153"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-13153-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,11]]},"assertion":[{"value":"4 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the institutional review board <b>of<\/b> Guangzhou Institute of Cancer Research, the Affiliated Cancer Hospital, Guangzhou Medical University, and written informed consent for publication was obtained from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1378"}}